

Mano Nakamura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2729834/publications.pdf>

Version: 2024-02-01

12
papers

600
citations

840776

11
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

1194
citing authors

#	ARTICLE	IF	CITATIONS
1	B Lymphocytes Accumulate and Proliferate in Human Skin at Sites of Cutaneous Antigen Challenge. <i>Journal of Investigative Dermatology</i> , 2022, 142, 726-731.e4.	0.7	2
2	Combined anti- <i>PD-1</i> and anti- <i>CTLA-4</i> checkpoint blockade: Treatment of melanoma and immune mechanisms of action. <i>European Journal of Immunology</i> , 2021, 51, 544-556.	2.9	71
3	IgE Activates Monocytes from Cancer Patients to Acquire a Pro-Inflammatory Phenotype. <i>Cancers</i> , 2020, 12, 3376.	3.7	15
4	IgE Antibodies against Cancer: Efficacy and Safety. <i>Antibodies</i> , 2020, 9, 55.	2.5	17
5	Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome. <i>Cells</i> , 2020, 9, 1631.	4.1	26
6	B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies. <i>Frontiers in Immunology</i> , 2020, 11, 622442.	4.8	39
7	Abstract CT141: Phase 1 trial of MOv18, a first-in-class IgE antibody therapy for cancer. <i>Cancer Research</i> , 2020, 80, CT141-CT141.	0.9	13
8	Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma. <i>Oncotarget</i> , 2019, 10, e1593811.	4.6	20
9	Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 453.	4.8	177
10	Anti-Folate Receptor- α IgE but not IgG Recruits Macrophages to Attack Tumors via TNF α /MCP-1 Signaling. <i>Cancer Research</i> , 2017, 77, 1127-1141.	0.9	58
11	BRAF inhibitors: resistance and the promise of combination treatments for melanoma. <i>Oncotarget</i> , 2017, 8, 78174-78192.	1.8	75
12	Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types. <i>Frontiers in Immunology</i> , 2017, 8, 1911.	4.8	87